Katsukunya Jonathan N, Naicker Revina, Soko Nyarai D, Blom Dirk, Sinxadi Phumla, Chimusa Emile R, Rayner Brian, Jones Erika, Dandara Collet
Division of Human Genetics, Department of Pathology and Institute of Infectious Disease and Molecular Medicine (IIDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
SAMRC/UCT Platform for Pharmacogenomics Research and Translation, South African Medical Research Council, Cape Town, South Africa.
Front Genet. 2025 Jun 4;16:1608423. doi: 10.3389/fgene.2025.1608423. eCollection 2025.
Genetic variation in genes coding for enzymes metabolising antihypertensive drugs, may affect the efficacy of angiotensin converting enzyme (ACE) inhibitors such as enalapril, potentially leading to resistant hypertension (RHTN). We set out to evaluate the contribution of genetic variation in and genes on susceptibility to RHTN, as well as estimate the frequencies of copy number variation (CNV) in African and Mixed Ancestry (MA) populations of South Africa.
Using a retrospective age, sex and ethnicity matched case-control study design, 379 participants with hypertension belonging to the African and MA ethnic groups were recruited. Cases were participants with RHTN (i.e., blood pressure (BP) ≥140/90 mmHg on ≥3 antihypertensive drugs or BP < 140/90 mmHg on >3 antihypertensive drugs, including a diuretic). Cases were matched to controls with similar characteristics (age (±5 years), sex and ethnicity) in a 1:1 ratio. Controls were participants with hypertension that was under control (BP < 140/90 mmHg on ≤3 antihypertensive drugs). Five polymorphisms in and were characterized using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), quantitative PCR and validated using Sanger sequencing. The additive model of inheritance and multivariable logistic regression were used to determine associations between genotypes and RHTN while adjusting for potential confounding variables.
rs3918188A/A (aOR: 0.13; CI: 0.04-0.41; P = 0.0009) genotype and rs2070744-rs1798883-rs3918188G-T-A haplotype (OR: 0.54; CI: 0.37-0.78; P = 0.001) appeared to confer protection against RHTN among MA participants only. rs2244613C>A and CNV were not significantly associated with RHTN. However, there appeared to be quantitative differences in CNV profiles across ethnic groups. We speculate that rs3918188A allele may affect gene expression, potentially leading to increased amounts of the vasodilator, nitric oxide (NO) and favourable outcomes in individuals taking antihypertensives drugs such as enalapril.
genetic variation seems important in the susceptibility to RHTN among Africans and requires further studies.
编码代谢抗高血压药物的酶的基因中的遗传变异,可能会影响血管紧张素转换酶(ACE)抑制剂(如依那普利)的疗效,从而可能导致难治性高血压(RHTN)。我们旨在评估和基因中的遗传变异对RHTN易感性的影响,并估计南非非洲人和混合血统(MA)人群中拷贝数变异(CNV)的频率。
采用回顾性年龄、性别和种族匹配的病例对照研究设计,招募了379名属于非洲和MA族裔的高血压患者。病例为RHTN患者(即使用≥3种抗高血压药物时血压(BP)≥140/90 mmHg,或使用>3种抗高血压药物(包括利尿剂)时BP < 140/90 mmHg)。病例与具有相似特征(年龄(±5岁)、性别和种族)的对照以1:1的比例匹配。对照为血压得到控制的高血压患者(使用≤3种抗高血压药物时BP < 140/90 mmHg)。使用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)对和基因中的5种多态性进行了表征,并使用定量PCR进行了验证,同时使用桑格测序进行了确认。在调整潜在混杂变量的同时,使用遗传的加性模型和多变量逻辑回归来确定基因型与RHTN之间的关联。
rs3918188A/A(调整后比值比:0.13;置信区间:0.04 - 0.41;P = 0.0009)基因型和rs2070744 - rs1798883 - rs3918188G - T - A单倍型(比值比:0.54;置信区间:0.37 - 0.78;P = 0.001)似乎仅在MA参与者中对RHTN具有保护作用。rs2244613C>A和CNV与RHTN无显著关联。然而,不同种族之间的CNV谱似乎存在数量差异。我们推测rs3918188A等位基因可能会影响基因表达,从而可能导致血管舒张剂一氧化氮(NO)的量增加,并使服用依那普利等抗高血压药物的个体获得良好的治疗效果。
遗传变异在非洲人对RHTN的易感性中似乎很重要,需要进一步研究。